BRD2 inhibition: GSK620, a BRD2-selective inhibitor, reduces MMP9 expression by 60% and inhibits GBM cell invasion through Matrigel by 80% (Gilan et al., 2020). This evidence concerns the gene BRD2 and glioblastoma.